Angstrom Bio is a technology company.
Angstrom Bio has raised $3.0M across 1 funding round.
Angstrom Bio has raised $3.0M in total across 1 funding round.
Angstrom Bio has raised $3.0M in total across 1 funding round.
Angstrom Bio is a biotechnology company founded in 2019 and based in Austin, Texas, that develops advanced molecular diagnostics using amplicon sequencing, machine learning, and third-generation nanopore sequencing.[1][2][4][6] Its core product, the AMPD™ (Angstrom Massively Parallel Diagnostics) platform, enables cost-effective, high-throughput next-generation sequencing (NGS) for viral diagnostics, including COVID-19 detection and variant identification, as well as respiratory pathogen panels and antibody optimization.[1][2][6] The platform serves healthcare providers and patients by addressing limitations of traditional qPCR and sequencing-by-synthesis methods, offering superior sample throughput, multiplexing, resolution, speed, and cost for population-scale diagnostics.[2] In 2021, it secured $3 million in funding led by GreyBird Ventures, validating its technology through collaboration with the Walter Reed Army Institute of Research, with reported revenue around $8.6 million.[1][2][4]
Angstrom Bio emerged in 2019 amid the COVID-19 pandemic, focusing on leveraging machine intelligence, novel nucleotide chemistry, and nanopore sequencing to revolutionize diagnostics.[1][2][4][6] Led by CEO Carlos Santos, Ph.D., the company built its AMPD™ platform with proprietary PCR chemistry and bioinformatics, validated in partnership with the Walter Reed Army Institute of Research.[2] A pivotal moment came in June 2021 with a $3 million investment from GreyBird Ventures, enabling launches like a SARS-CoV-2 variant identification diagnostic and development of multi-pathogen respiratory panels for viruses (e.g., influenza, RSV) and bacteria.[1][2] This funding and validation marked early traction, positioning Angstrom to scale beyond COVID-19 into broader infectious disease detection.[2]
Angstrom Bio stands out in diagnostics through these key advantages:
Angstrom Bio rides the wave of next-generation sequencing (NGS) and AI-driven diagnostics, accelerated by the COVID-19 pandemic's demand for rapid, scalable pathogen detection.[1][2][6] Its timing aligns with nanopore tech's maturation—offering portable, real-time sequencing—amid market forces like rising infectious disease threats, antimicrobial resistance, and the need for multiplexed tests over single-analyte qPCR.[2] By enabling cheaper, faster population-scale molecular diagnostics, it influences the digital health ecosystem (11,252 companies) and AI in healthcare (7,146 companies), reducing barriers to advanced testing in resource-limited settings and supporting global surveillance of variants.[1] This positions Angstrom as a bridge between biotech hardware innovation and AI software, potentially expanding to treatment applications like antibody design.[1][4]
Angstrom Bio's trajectory points to expanded respiratory panels, broader infectious disease applications, and potential therapeutic tools like AI-optimized antibodies, building on its AMPD™ foundation and post-2021 momentum.[1][2] Trends in portable nanopore sequencing, AI bioinformatics, and post-pandemic preparedness will propel growth, especially as demand rises for multiplexed, variant-agnostic diagnostics amid evolving threats like novel coronaviruses.[2] Its influence could grow by partnering with health systems and governments, evolving from COVID responder to ecosystem leader in scalable molecular health tech—cementing its role in making advanced diagnostics as accessible as population-scale testing demands.
Angstrom Bio has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in June 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2021 | $3.0M Seed |